Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Avita Medical, Inc. (RCEL)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$16.32+6.46%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RCEL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage debt and capital allocation to support growth | A supporting condition in Avita Medical, Inc.'s published investment case. The stated target is No new debt issues that worsen leverage. | Under Pressure | New debt issuance that increases financial risk materially | New 5-yr senior secured debt issued Jan 2026; warrant exercised Nov 2026 RCEL entered a 5-year senior secured credit facility with Perceptive in Jan 2026 and exercised warrants in Nov 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
RCEL is a higher-risk growth business, not yet a proven profitable compounder. The multi-year view is on watch: revenue growth is progressing, while recent financial performance remains below its industry cohort.
The valuation model shows RCEL at a substantial premium to peers, with low confidence in that comparison. Its priced-in status is tagged justified and no fragility gates fired, but the negative expectations gap suggests the market’s assumptions may leave limited room for execution to disappoint.
Near term, revenue growth is the clearest positive: second-quarter revenue rose 18% year over year and 13% sequentially, while gross margin remained near 82%. Operating expenses were lower year over year, but expense discipline is rated behind, and RCEL remains loss-making with elevated risk and erratic recent earnings surprises.
Over the next few quarters, the thesis depends on maintaining growth without reversing the recently raised guidance, while improving expense discipline and protecting margins. A weakening jobs trend could weigh on cyclical healthcare names, while continued strong results and guidance from sector peers could support the sector backdrop.
Over a 1-to-3-year horizon, RCEL has a growing business and a supportive sector backdrop, but its loss-making position, premium versus peers, and execution risks keep the long-term thesis conditional. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management delivers on growth initiatives and leadership stability |
| A supporting condition in Avita Medical, Inc.'s published investment case. The stated target is Maintain or improve progress score above 70%. |
| Intact |
| Progress score falls below 50% or leadership changes disrupt growth |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Losses reduce and move toward breakeven | A primary condition in Avita Medical, Inc.'s published investment case. The stated target is EPS loss narrows toward -$0.35 next quarter and improves thereafter. | Improving | EPS loss worsens beyond -$0.5 next quarter | Diluted EPS: $-0.25 per share FY2026-Q4; GAAP. Published target: EPS loss narrows toward -$0.35 next quarter and improves thereafter. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 6, 2026-0.25 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows to about $82.5M in 2026 | A primary condition in Avita Medical, Inc.'s published investment case. The stated target is ~$82.5M. | Intact | Revenue falls below $70M in FY26 | Revenue: $21.702M FY2026-Q4; GAAP. Published target: ~$82.5M. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 202621,702,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.85 → $-0.38 · observed estimates
$0.15B → $0.11B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.85 | $151,834,570 | 4 / 7 |
| 2026-07-25 | $-0.85 | $151,834,570 | 4 / 7 |
| 2026-07-26 | $-0.85 | $151,834,570 | 4 / 7 |
| 2026-07-27 | $-0.85 | $151,834,570 | 4 / 7 |
| 2026-07-28 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-07-29 | $-0.85 | $151,834,570 | 4 / 7 |
| 2026-07-30 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-07-31 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-01 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-02 | $-0.85 | $151,834,570 | 4 / 7 |
| 2026-08-03 | $-0.85 | $151,834,570 | 4 / 7 |
| 2026-08-04 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-05 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-06 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-07 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-08 | $-0.82 | $152,605,000 | 3 / 7 |
| 2026-08-09 | $-0.82 | $152,605,000 | 3 / 7 |
| 2026-08-10 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-12 | $-0.84 | $156,971,430 | 3 / 7 |
| 2026-08-13 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-14 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-15 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-16 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-17 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-18 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-19 | $-0.54 | $100,050,000 | 3 / 5 |
| 2026-08-20 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-08-21 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-08-22 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-08-23 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-08-24 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-08-25 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-08-26 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-08-27 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-08-28 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-08-29 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-08-30 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-08-31 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-01 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-02 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-03 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-04 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-05 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-06 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-07 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-08 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-09 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-10 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-11 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-12 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-13 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-14 | $-0.38 | $110,100,000 | 3 / 5 |
| 2026-09-15 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-16 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-17 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-18 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-19 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-20 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-21 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-22 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-23 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-24 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-25 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-26 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-27 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-28 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-29 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-09-30 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-01 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-02 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-03 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-04 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-05 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-06 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-07 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-08 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-09 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-10 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-11 | $-0.38 | $110,157,143 | 3 / 5 |
| 2026-10-12 | $-0.38 | $110,157,143 | 2 / 5 |
| 2026-10-13 | $-0.38 | $110,157,143 | 1 / 5 |
| 2026-10-14 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-15 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-16 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-17 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-18 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-19 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-20 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-21 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-22 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-23 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-24 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-25 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-26 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-27 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-28 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-29 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-30 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-10-31 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-11-01 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-11-02 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-11-03 | $-0.38 | $110,157,143 | 3 / 3 |
| 2026-11-04 | $-0.38 | $110,157,143 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.